Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LB-102 in Healthy Volunteers
NCT04187560Phase 1Completed
- Sponsor
- LB Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LP-102 in schizophrenia (8 cohorts), sponsored by LB Pharmaceuticals. Primary endpoint: Percentage of participants who experience at least one treatment-emergent adverse event (TEAE). Started Jan 2020; status: completed.
02
Drugs
LP-102
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04187560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187560.